Monte Rosa Therapeutics (GLUE) Free Cash Flow Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Monte Rosa Therapeutics |
1.83 Bn |
1.15 Bn |
- |
14.32% |
| Date | Value |
|---|
| Mar 31, 2026 |
14.32% |
| Dec 31, 2025 |
-129.57% |
| Sep 30, 2025 |
566.40% |
| Jun 30, 2025 |
-24.87% |
| Mar 31, 2025 |
-16.98% |
| Dec 31, 2024 |
183.81% |
| Sep 30, 2024 |
18.86% |
| Jun 30, 2024 |
17.55% |
| Mar 31, 2024 |
-40.78% |
| Dec 31, 2023 |
245.54% |
| Sep 30, 2023 |
-24.89% |
| Jun 30, 2023 |
-58.82% |
| Mar 31, 2023 |
4.41% |
| Dec 31, 2022 |
-86.42% |
| Sep 30, 2022 |
13.28% |
| Jun 30, 2022 |
-100.68% |
| Mar 31, 2022 |
-81.46% |
| Dec 31, 2021 |
-101.44% |
| Sep 30, 2021 |
-245.94% |
